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Repurposing screen identiﬁes mebendazole as a clinical
candidate to synergise with docetaxel for prostate
cancer treatment
Linda K. Rushworth1,2, Kay Hewit2, Sophie Munnings-Tomes3, Sukrut Somani4, Daniel James2, Emma Shanks2, Christine Dufès4,
Anne Straube3, Rachana Patel2 and Hing Y. Leung1,2
BACKGROUND: Docetaxel chemotherapy in prostate cancer has a modest impact on survival. To date, efforts to develop
combination therapies have not translated into new treatments. We sought to develop a novel therapeutic strategy to tackle
chemoresistant prostate cancer by enhancing the efﬁcacy of docetaxel.
METHODS: We performed a drug-repurposing screen by using murine-derived prostate cancer cell lines driven by clinically
relevant genotypes. Cells were treated with docetaxel alone, or in combination with drugs (n= 857) from repurposing libraries, with
cytotoxicity quantiﬁed using High Content Imaging Analysis.
RESULTS: Mebendazole (an anthelmintic drug that inhibits microtubule assembly) was selected as the lead drug and shown to
potently synergise docetaxel-mediated cell killing in vitro and in vivo. Dual targeting of the microtubule structure was associated
with increased G2/M mitotic block and enhanced cell death. Strikingly, following combined docetaxel and mebendazole treatment,
no cells divided correctly, forming multipolar spindles that resulted in aneuploid daughter cells. Liposomes entrapping docetaxel
and mebendazole suppressed in vivo prostate tumour growth and extended progression-free survival.
CONCLUSIONS: Docetaxel and mebendazole target distinct aspects of the microtubule dynamics, leading to increased apoptosis
and reduced tumour growth. Our data support a new concept of combined mebendazole/docetaxel treatment that warrants
further clinical evaluation.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0681-5
BACKGROUND
Prostate cancer is the second most common cause of cancer
deaths in men in the Western world.1 For advanced disease at
diagnosis, androgen-deprivation therapy (ADT) remains the main
treatment option. Docetaxel is currently the standard cytotoxic
regime routinely used to treat metastatic prostate cancer;
however, treatment with this drug leads to only a modest
increase in median survival.2,3 Recent evidence from clinical trials
giving hormone-sensitive patients upfront treatment of doce-
taxel in combination with ADT has demonstrated a robust
increase in survival. Subsequently, upfront ADT combination
therapy with either chemotherapy or androgen receptor path-
way inhibitors has become routinely utilised.2,4–6 Despite initial
response, however, the majority of tumours relapse within 2–3
years, due to de novo resistance or the emergence of treatment-
resistant prostate cancer. In contrast to successes observed
in other tumours, including breast cancer,7 efforts to develop
combination therapies to incorporate docetaxel have not
translated into new treatment regimes in prostate cancer.8
The use of prostate cancer model systems driven by clinically
relevant molecular lesions may identify novel drugs to synergise
docetaxel-mediated antitumour effects.
Inactivation of the tumour suppressor PTEN plays a critical role
in prostate carcinogenesis. In some tumours, WNT-driven β-
catenin activation in combination with PTEN deﬁciency mediates
metastatic castration-resistant prostate cancer (CRPC).9,10 Similarly,
aberrant cellular signalling associated with combined PTEN and
Sprouty2 (SPRY2) inactivation can drive aggressive, treatment-
resistant prostate cancer.11 Together, these genetic alterations
represent a signiﬁcant portion of prostate tumours. We therefore
developed and characterised genetically modiﬁed murine models
with prostate tumour-speciﬁc alterations: (1) PbCre Ctnnb1(ex3Δ)/+
Ptenﬂ/+, with heterozygous deletion of Ctnnb1 exon 3, leading to
constitutive β-catenin activation and heterozygous loss of Pten in
the prostatic epithelium; (2) PbCre Spry2ﬂ/+ Ptenﬂ/ﬂ, with hetero-
zygous loss of Spry2 and homozygous loss of Pten.11 Prostate
cancer cell lines were generated from the PbCre Ctnnb1(ex3Δ)/+
Ptenﬂ/+ and PbCre Spry2ﬂ/+ Ptenﬂ/ﬂ tumours, hereafter referred to
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as CP2 and SP1 cells, respectively. These murine prostate cancer
cells form prostate orthografts in immune-compromised nude
mice with evidence of metastatic disease, thus recapitulating
clinically invasive prostate cancer.
Drug repurposing may fast-track previously unpredicted uses of
available drugs. As drugs considered for repurposing have well-
characterised pharmacodynamic properties and toxicities, the
development time and cost to reach the clinic can be minimised.
High-throughput screening of repurposing agents allows the
concurrent testing of drug libraries to identify putative candidate
therapeutics,12 e.g. the use of thalidomide in multiple myeloma.13
We conducted a drug-repurposing screen to identify novel
therapeutic drugs to combine with docetaxel to treat invasive
prostate cancer. The anti-parasitic drug mebendazole was
identiﬁed as the top candidate to synergise with docetaxel to
inhibit cell growth, with suppression of cell cycle progression and
increased cell death. This is a result of major disruption to the
microtubule network, causing cells to form multipolar spindles
and fail to divide correctly.
METHODS
Methodology for multiple experiments
Details for the following experiments are described in Supple-
mentary Information: cell survival assay, FACS and cell cycle
analysis, confocal microscopy and formulation and physicochem-
ical characterisation of liposomes.
Cell culture
CP2 and SP1 cells were derived from genetically modiﬁed mouse
prostate cancer models that represent activation of β-catenin and
inactivation of Sprouty2 along with the loss of Pten tumour-
suppressor protein, respectively.10,11 Details of the CP2 (RRID:
CVCL_VQ85) and SP1 (RRID:CVCL_VQ86) cell lines have been
deposited on the RRID Portal (https://scicrunch.org/resources/).
Cells were grown in DMEM supplemented with 10% foetal bovine
serum (FBS) and 2 mM L-glutamine. LNCaP and PC3 cells were
obtained from American Type Culture Collection and were grown
in RPMI supplemented with 10% FBS and 2 mM L-glutamine. RPE1
cell lines stably expressing H2B-RFP, GFP-tubulin or EB3-GFP were
maintained in the DMEM/F-12 medium supplemented with 10%
FCS, 2.3 g/l sodium bicarbonate, 100 U/ml penicillin, 100 μg/ml
streptomycin and 500 µg/ml geneticin. Cell lines were authenti-
cated by LCG standards or in-house using Promega GenePrint
10 Kit. All cell lines used were routinely tested every 6 months
for mycoplasma using an in-house MycoAlert™ Mycoplasma
Detection Kit (Lonza, Switzerland), according to the
manufacturer’s instructions. RPE1 cells were tested monthly for
mycoplasma using a MycoSensor PCR Assay Kit (Agilent
Technologies, USA).
Drug libraries
The repurposing libraries used in the screen were the NIH Clinical
Collection and NIH Approved Oncology Collection. The Clinical
Collection contains 727 small molecules previously used in Phase
I–III human clinical trials, and the Oncology Collection contains
130 of the most current FDA-approved anticancer drugs. Libraries
were purchased from the NCI Developmental Therapeutic
Program's Open Compound Repository, NIH National Cancer
Institute (Maryland, USA).
Repurposing screen
Initial experiments were undertaken to establish a robust screen-
ing plan. The optimal seeding densities for the cell lines were
ascertained for plating cells in 384-well plates, and dose–response
curves for an EC30 of docetaxel were carried out and tested
extensively in mock screens. CP2 and SP1 cells were plated out in
384-well plates and treated for 48 h with docetaxel or DMSO in
combination with the library drugs. The drugs from the compound
libraries were assayed at three different concentrations (0.1, 1 and
10 µM), and all conditions were tested in triplicate. Cells were ﬁxed
and stained with DAPI, and the readout was cytotoxicity,
quantiﬁed by nuclear count using High Content Imaging Analysis
(Operetta, Perkin Elmer). Staurosporine (1 µM) was used as a
positive control for cytotoxicity. To determine a positive inhibitory
test, the mean of the percentage inhibition (PI) in docetaxel-only
wells was calculated. The mean PI for the triplicate wells
containing library drugs and docetaxel had to be greater than
the mean PI of docetaxel-alone wells by 10%. The quality of the
screen was assessed primarily using the Z-prime for each plate,
and all performed well (average Z-prime value 0.73; max 0.94,
min 0.51).
Synergy assay
Cells were seeded in 96-well opaque white plates and treated the
following day with various combinations of drugs in a checker-
board system. Each plate contained 8 × 8-dose matrix blocks with
serial twofold dilutions of docetaxel and 1.333-fold dilutions of
mebendazole. Additional wells were reserved for untreated and
vehicle-treated control wells. Forty-eight hours later, the percen-
tage of growth inhibition was assayed using the CellTiter-Glo
Assay (Promega). The combination index (CI) was calculated using
CompuSyn software, where <1 indicates synergism,= 1 is an
additive effect and >1 indicates antagonism.14
Live-cell imaging
Cells were seeded into glass-bottom dishes (World Precision
Instruments), coated with 10 µg/ml ﬁbronectin (Sigma), on the
day prior to imaging. In all, 2 nM docetaxel, 200 nM mebenda-
zole, both drugs or DMSO as a control was diluted in growth
medium and added to cells immediately before transferring
the dish to the microscope-stage incubator (Tokai Hit) heated to
37 °C with 5% CO2. RPE1 cells stably expressing EB3-GFP were
imaged between 30 and 75 min after drug addition for 100
frames at 1 frame per second using a ×100 NA 1.4 objective on
an Olympus personal Deltavision microscope (Applied Precision,
LLC) using a GFP ﬁlter set (Chroma) and a Coolsnap HQ camera,
controlled by Softworx (Applied Precision, LLC). Kymographs
were generated from radial lines drawn on the maximum-
projected movies and comets traced to measure average
microtubule assembly speed from 15 cells for each condition.
RPE1 cells stably expressing H2B-RFP or PC3 cells stained with
5 µM SiR-DNA were imaged for > 50 h at 1 frame per 10 min
using a ×10 NA 0.3 dry objective on an Olympus personal
Deltavision microscope (Applied Precision, LLC) using a mCherry
ﬁlter set (Chroma) and a Coolsnap HQ camera, controlled by
Softworx (Applied Precision, LLC). For each condition, mitotic
timing and outcome were analysed in at least 100 (RPE1) or 50
cells (PC3). RPE1 cells stably expressing GFP-tubulin and stained
with 5 µM SiR-DNA were imaged for 12 h at 1 frame per 5 min
using a ×40 NA 1.2 objective on an Olympus personal
Deltavision microscope (Applied Precision, LLC) using GFP and
mCherry ﬁlter sets (Chroma) and a Coolsnap HQ camera,
controlled by Softworx (Applied Precision, LLC).
In vitro liposome-mediated anti-proliferative activity
Anti-proliferative activity of liposomes encapsulating mebenda-
zole and/or docetaxel was assessed using a standard MTT assay
(Sigma-Aldrich). PC3M-Luc-G5 cells were seeded at a density of
5000 cells/well in 96-well plates for 24 h. For LNCaP, 96-well
plates were pre-coated with poly-L-lysine solution (6.4 µg/mL,
50 µl per well) overnight. The coating solution was removed,
and the plates were washed with PBS (pH 7.4) prior to seeding
LNCaP cells at the density of 10,000 cells/well for 24 h.
The cells were treated with the liposomal formulation encapsu-
lating docetaxel (0–20 nM), with the liposomal formulation
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encapsulating mebendazole (0–182.5 nM) or with liposomal
formulation encapsulating both drugs at the concentrations
mentioned previously for 48 h. The ratio of mebendazole to
docetaxel in the formulation was maintained at 9:1. Untreated
cells were used as negative controls, and cells treated with 1%
Triton X as positive controls. Absorbance was measured at
570 nm using a plate reader.
In vivo liposome-mediated activity in a subcutaneous xenograft
model
The in vivo experiments were carried out in accordance with the
UK Home Ofﬁce regulations (UK Animals (Scientiﬁc Procedures)
Act 1986) under Project Licence P32E328B7.
PC3M-Luc-G5 cancer cells in exponential growth were sub-
cutaneously injected into both ﬂanks of 7-week-old male
immunodeﬁcient BALB/c mice (1 × 106 cells per ﬂank). Mice were
ordered from Charles River (UK), housed in randomised groups of
ﬁve, at 19–23 °C with a 12-h light–dark cycle and were fed a
conventional diet (Rat and Mouse Standard Expanded, B&K
Universal, UK) with water ad libitum. They were housed in an
enriched environment, with igloos, cardboard tubes and chewing
sticks. When tumours were palpable and reached a diameter of
5 mm, groups of ﬁve mice (thus ten tumours per treatment group)
received the following treatments: empty liposomes, untargeted
liposomes entrapping docetaxel or mebendazole, untargeted
liposomes entrapping docetaxel and mebendazole and transferrin
(Tf)-bearing liposomes entrapping docetaxel and mebendazole
(for direct comparison with untargeted liposomes entrapping
docetaxel and mebendazole). Each mouse received ﬁve intrave-
nous tail vein injections (20 mg of docetaxel and 180mg of
mebendazole per kg of body weight per injection) once every
2 days for 10 days (last treatment on day 9). The weight of the
animal was measured daily as a surrogate marker of the toxicity of
the treatments. One animal from the group treated with
transferrin (Tf)-bearing liposomes entrapping docetaxel and
mebendazole was removed from the study due to an eye issue
(unrelated to treatment). The tumour volume was determined by
calliper measurements (volume= d3 × π/6), with a deﬁned end-
point of tumour diameter 10 mm. Mice were euthanised humanely
by CO2 inhalation. The results are expressed as relative tumour
volume (rel. Voltx= Voltx/Volt0) and responses classiﬁed analo-
gous to Response Evaluation Criteria in Solid Tumours (RECIST)
guidelines. Progressive disease is deﬁned as an increase in relative
tumour volume higher than 1.2-fold, stable disease as a relative
volume between 0.7 and 1.2 of starting volume and partial
response as measurable tumour with a volume reduction of more
than 30% (0–0.7).
The therapeutic efﬁcacy of these treatments was also assessed
by bioluminescence imaging, using an IVIS Spectrum (Caliper Life
Sciences, Hopkinton, MA). Mice bearing subcutaneous PC3M-Luc-
G5 tumours were intravenously injected with treatments as
described above. On alternate days (Days 1, 3, 5, 7 and 9),
animals were intraperitoneally injected with the luciferase
substrate D-luciferin (150 mg/kg body weight), then anaesthetised
using isoﬂurane inhalation 10min before imaging. The light
emitted from the bioluminescent tumours was detected for 2 min
using Living Image software (Perkin Elmer, Waltham, MA) and
displayed as a pseudo-colour overlay onto a greyscale image of
the animal. Identical illumination settings were used for acquiring
all images.
Statistics
Data plotting and statistical analyses, including two-way ANOVA,
Welch’s t test (unpaired, two tailed), Mann–Whitney, Kaplan–Meier
survival analysis and log rank (Mantel–Cox), were carried out using
GraphPad Prism 7. Graphs are shown as mean ± standard
deviation (SD) or standard error of the mean (SEM) with individual
points shown.
RESULTS
A repurposing screen identiﬁes drugs that increase docetaxel
efﬁcacy
We performed a drug-repurposing screen in cell lines derived
from aggressive tumours developed in Pbcre Ctnnb1(ex3Δ)/+ Ptenﬂ/+
and PbCre Spry2ﬂ/+ Ptenﬂ/ﬂ mice (CP2 and SP1 cells, respectively).
These tumours resulted from genetic alterations to important
signalling pathways in prostate cancer, making them clinically
highly relevant.10,11 CP2 and SP1 cells signify carcinogenesis
driven by WNT and Ras-MAPK pathways, respectively (Supple-
mentary Fig. S1A). The screen workﬂow is summarised in
Supplementary Fig. S1B, C. Brieﬂy, CP2 and SP1 cells were treated
with docetaxel (at predicted EC30: CP2, 7 nM; SP1, 5 nM,
respectively; Supplementary Fig. S1D) or DMSO in combination
with drugs from two repurposing libraries—NIH Clinical Collection
and NIH Approved Oncology Collection. The drugs were assayed
at three different concentrations (0.1, 1 and 10 µM), and the
readout was cytotoxicity quantiﬁed by nuclear count. The
percentage growth inhibition relative to the DMSO control for
each drug was calculated. The drug window that would support
combination therapy was deﬁned as a ≥ 10% increase in growth
inhibition when combined with docetaxel.
A total of 820 unique drugs were tested in the primary screen,
with some overlap (n= 37) between the two libraries. Analysis of
the percentage growth inhibition of the 37 duplicated drugs
showed that these caused similar effects, providing a convenient
internal quality control (Supplementary Fig. S1E). One of the drugs
was docetaxel itself, which at 0.1 µM resulted in 80–90% inhibition
in both cell lines as expected (Supplementary Fig. S1F). Other well-
known anticancer drugs were also effective as single agents in
both cell lines at the lowest concentration tested. Most of the
drugs however had little or no effect on either cell line at 0.1 µM
(Supplementary Fig. S1F).
Drugs exhibiting ≥ 10% increase in growth inhibition when
combined with docetaxel were identiﬁed (Fig. 1a; Supplementary
S1G, H). Relatively fewer hits were identiﬁed in SP1 cells (Fig. 1a;
Supplementary S1I; Table S1), which likely reﬂects the actual
percentage inhibition achieved by docetaxel alone in the screen,
at 17 and 42%, respectively for SP1 and CP2 cells. Among the top
hits for CP2 cells were the anthelmintic family of drugs. This
includes albendazole, ﬂubendazole and mebendazole, which
showed additional effects on cell survival with docetaxel at all
concentrations tested (except albendazole at 0.1 µM and meben-
dazole at 10 µM; Fig. 1b). These drugs are anti-parasitics used to
expel worms by suppressing microtubule assembly. Importantly,
mebendazole was the only drug that increased the percentage
growth inhibition in both cell lines, albeit to a lesser extent in
SP1 cells (Supplementary Fig. S1J), suggesting that this family of
drugs may provide a combinatorial docetaxel effect, irrespective
of genetic alteration. Two of these drugs, mebendazole and
albendazole, were selected for validation along with other lead
candidates, dabrafenib, honokiol and nobiletin (Supplementary
Table S2 provides the current uses of these drugs, as well as
detailing previous cancer studies and associations with prostate
cancer). All of these drugs have shown previous efﬁcacy in
multiple cancer models both in vitro and in vivo. To validate these
drugs, incremental doses of docetaxel (n= 8, 5.3–40 nM) were
combined with target compounds in CP2 and SP1 cells, and
human LNCaP prostate cancer cells. Among the ﬁve hits evaluated
(Fig. 1c; Supplementary Fig. S2A), mebendazole showed the
greatest combinatorial effect with docetaxel in a dose-dependent
manner, particularly in SP1 and LNCaP cells (Fig. 1c). Mebendazole
was therefore tested in additional survival assays.
Docetaxel inhibits the depolymerisation of microtubules by
binding to the inner surface of β-tubulin, while mebendazole
inhibits the polymerisation of microtubules by binding to tubulin
dimers at the colchicine site (Fig. 2a).15 We therefore hypothesised
that these drugs may work together to synergistically affect the
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microtubule dynamics. Combining mebendazole with docetaxel
decreased cell survival in both CP2 (Fig. 2b) and SP1 cells
(Supplementary Fig. S2B). Similar to the observed effects in human
LNCaP cells (Fig. 1c), combining docetaxel and mebendazole
showed enhanced suppression of PC3 cell survival (Fig. 2c). As a
single agent, mebendazole was also able to decrease cell survival
in docetaxel-resistant cells (PC3M DocR) to a similar extent as the
parental PC3M cells, suggesting that mebendazole may have the
potential to be used as treatment for docetaxel-resistant prostate
cancers (Fig. 2d).
Docetaxel and mebendazole work together to increase apoptosis
We wanted to ascertain if the use of mebendazole and docetaxel
simultaneously resulted in synergistic cell growth inhibition. The
combination index (CI) determines whether the combination is
synergistic (< 1), additive (= 1) or antagonistic (> 1).14 Using a
luminescence proliferation assay, we calculated the percentage
growth inhibition and CI for docetaxel and mebendazole using
dose curves in a checkerboard manner (Fig. 3a). In the mouse cell
lines, as well as the human cell lines LNCaP, PC3 and CWR22,
synergy between the drugs was seen, particularly at lower
concentrations. For example, for 1.25 nM docetaxel and 237 nM
mebendazole, the CI values for SP1, CP2, LNCaP, PC3 and CWR22
cells are 0.48, 0.71, 0.39, 0.78 and 0.80, respectively, conﬁrming
that the drugs are synergistic at these concentrations in all the cell
lines tested.
Cell cycle analysis of SP1 and PC3 cells revealed enhanced G2/M
and sub-G1 fractions following combined docetaxel and meben-
dazole treatment (Fig. 3b, c). Furthermore, apoptosis in SP1 and
CP2 cells was induced following combined treatment (Fig. 3d;
Supplementary Fig. S3A). Untransformed RWPE human prostate
epithelial cells were less responsive to the two drugs in isolation
than cancer cells (Supplementary Table S3), although a degree of
synergism to combined treatment was observed (Supplementary
Fig. S3B). Since mebendazole binds to the colchicine-binding site
of the tubulin dimer, colchicine was also studied and shown to
enhance docetaxel-induced cell death, providing mechanistic
support for therapeutic synergism arising from distinct interac-
tions within the microtubule structure (Supplementary Fig. S3C).
Combining docetaxel and mebendazole perturbs microtubule
dynamics and leads to aberrant mitosis
Given that the primary target of both drugs is tubulin, we wanted
to look more closely at the microtubule network. Tubulin can be
modiﬁed in various ways, including detyrosination, which
accumulates in stable microtubules.16 We performed confocal
microscopy in PC3 and SP1 cells using antibodies against
detyrosinated tubulin to study the effect of the drug combinations
on microtubule stability (Fig. 4a, b). Docetaxel-treated cells
showed signiﬁcantly elevated levels of detyrosinated tubulin.
The addition of mebendazole interestingly signiﬁcantly reduced
docetaxel-mediated accumulation of detyrosinated tubulin. These
data suggest that the two drugs in isolation have distinct effects
on microtubule stability. Microtubule dynamics were then studied
in RPE1 (hTERT retinal pigment epithelium 1-positive) cells stably
expressing a GFP-tagged end-binding protein EB3 to visualise
microtubule growing ends. Treatment with docetaxel reduced
growth speed slightly compared with the control cells, while
mebendazole decreased growth speed to a much greater extent
(Fig. 4c). Combining the drugs did not signiﬁcantly further reduce
microtubule growth compared with mebendazole alone.
The use of histone H2B as a nuclear marker helps to determine
the mitotic timing, deﬁned as time from chromosome condensa-
tion to anaphase (Fig. 5a). Studying RPE1 cells expressing H2B-RFP,
the median time spent in mitosis was signiﬁcantly increased with
combined treatment (Fig. 5a). Analysis of mitotic outcome
revealed that docetaxel treatment had a large effect on the
number of daughter cells with abnormal, fragmented nuclei
(Fig. 5b). Perhaps surprisingly given its profound effect on
microtubule growth speed in RPE1 cells, mebendazole as a single
agent had little effect on mitotic outcome. All cells treated with
mebendazole alone successfully divided, compared with only 61%
of docetaxel-treated cells. Combined treatment had a profound
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Fig. 1 Drug-repurposing screen identiﬁes drugs that increase
docetaxel efﬁcacy. a Venn diagram of screen results. The
percentage growth inhibition for each drug in combination with
docetaxel relative to the DMSO control was calculated. The number
of drugs with a ≥ 10% increase is shown for each concentration.
b CP2 cells were treated with the indicated anthelmintics, combined
with either docetaxel or DMSO. The percentage growth inhibition
for each drug in combination with docetaxel relative to the DMSO
control was calculated. n= 3 (technical replicates), mean values ± SD
are shown, analysed by two-way ANOVA with Sidak’s multiple
comparisons test, *p < 0.01, **p < 0.001, ***p < 0.0001. c CP2, SP1 and
LNCaP cells were treated with mebendazole at the indicated
concentrations or DMSO control, in combination with docetaxel at
a range of concentrations for 48 h. Cells were ﬁxed, stained with
DAPI and cytotoxicity quantiﬁed by nuclear count using High
Content Imaging Analysis (Operetta, Perkin Elmer). The percentage
growth inhibition relative to the DMSO control for each docetaxel
concentration (left panels), and the percentage cell survival after
treatment with the target drugs alone (right panels) were calculated.
n= 3 (technical replicates), mean values ± SD are shown.
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effect on spindle formation, resulting in a severe increase in
multipolar divisions, in addition to a high prevalence of
fragmented nuclei. Strikingly, none of the combination-treated
cells divided properly, so even though 36% of cells had two nuclei
moving apart, in no case were both nuclei normal. (Supplemen-
tary Fig. S4 provides examples of the classes of mitotic outcome.)
GFP-tubulin-expressing RPE1 cells allowed more detailed investi-
gation into mitotic spindle formation using time-lapse microscopy
(Fig. 5c). DMSO-treated cells showed distinct poles with proper
formation of the mitotic spindle and metaphase plate, while
combination therapy produced multipolar spindles with failure to
congress chromosomes, resulting in three abnormal daughter
cells. Similarly, combination treatment of PC3 cells also increased
the median time spent in mitosis and the percentage of
daughter cells with aberrant nuclei (Fig. 5d, e). Interestingly, the
effect on PC3 cells was even more pronounced than that on
the RPE1 cells, with 92% of cells failing to undergo mitosis to
produce two nuclei. This failure to divide correctly is consistent
with the observed increase in G2/M block and cell death (Fig. 3b–d;
Supplementary S3A).
In vitro and in vivo evaluation with liposome-mediated
combination treatment
In order to test the drug combination as a proof-of-concept
experiment, we employed liposomes encapsulating docetaxel,
mebendazole or both drugs. In addition, transferrin (Tf)-bearing
liposomes entrapping both docetaxel and mebendazole were
prepared for head-to-head comparison with untargeted liposomes
encapsulating both drugs. Transferrin targets the liposomes to
cancer cells expressing increased levels of the transferrin
receptor.17–19 The ratio of mebendazole to docetaxel in the
combination liposomes was stable at 9:1, and the liposomal
formulations were all <150 nm in size (<200 nm is essential for the
enhanced permeation and retention (EPR) effect) (Supplementary
Table S4).
To assess the anti-proliferative activity of the liposomes in vitro,
liposomes encapsulating mebendazole and/or docetaxel were
assessed using an MTT assay in PC3M-Luc-G5 and LNCaP cells.
Cells were treated with liposomal formulations encapsulating
docetaxel (0–20 nM), mebendazole (0–182.5 nM) or both drugs at
the same concentrations (Supplementary Fig. S5). The ratio of
mebendazole to docetaxel in the formulation was maintained at
9:1. Tf-targeted and untargeted liposomes containing combined
docetaxel and mebendazole were shown to have comparable
in vitro efﬁcacy, with transferrin targeting achieving higher
efﬁcacy in suppressing cell survival, particularly in LNCaP cells
treated with lower combined drug doses.
In vivo efﬁcacy was evaluated in a subcutaneous PC3M-Luc-G5
xenograft model.20 Brieﬂy, PC3M-Luc-G5 cells were subcuta-
neously injected into both ﬂanks of male immunodeﬁcient
BALB/c mice. Animals were treated intravenously every 2 days
for 9 days (20 and 180mg/kg of body weight per injection for
docetaxel and mebendazole, respectively) with empty liposomes,
untargeted liposomes entrapping docetaxel or mebendazole,
untargeted liposomes entrapping docetaxel and mebendazole
or Tf-bearing liposomes entrapping docetaxel and mebendazole.
Experimental mice injected with Tf-bearing liposomes containing
both docetaxel and mebendazole are to be directly compared
with mice treated with untargeted liposomes entrapping both
drugs in order to investigate the in vivo impact of transferrin-
mediated delivery of the liposome complex.
Treatment with untargeted and Tf-bearing liposomes entrap-
ping docetaxel and mebendazole abolished tumour growth
(Fig. 6a). During treatment (ﬁrst 9 days), tumours regressed with
dual-drug (untargeted and targeted) treatment, contrasting to
continued growth during singleton treatments (Fig. 6a). At the
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end of treatment, tumours were categorised as progressive, stable
or partially regressed (according to RECIST guidelines). Tumours
treated with untargeted and Tf-bearing liposomes entrapping
both drugs were classiﬁed as partially regressed at 50% and 90%,
respectively, compared with the progressive nature of the majority
of tumours treated with either liposomes containing singleton
drug or empty liposomes (Fig. 6b). Bioluminescence imaging of
PC3M-Luc-G5 tumours also showed superior efﬁcacy with dual
treatment, which resulted in reduced luminescence signals
(Supplementary Fig. S6A). No signiﬁcant variations of animal
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Fig. 4 Combining docetaxel and mebendazole perturbs microtubule dynamics by reducing microtubule assembly speed. a PC3 and
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detyrosinated tubulin (red) and total tubulin (green) and visualised using confocal microscopy (scale bar is 20 µm). For each cell line,
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representative images. The right panel shows microtubule assembly speeds measured from 15 cells for each condition as indicated. Data were
pooled from two independent experiments. n= 15, mean values ± SD are shown, analysed by one-way ANOVA with Tukey’s multiple
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body weight (Supplementary Fig. S6B) or apparent toxicities were
observed.
We deﬁned progression-free survival as < 20% increase from
starting tumour volume (day 1). Mice treated with untargeted
liposomes containing both docetaxel and mebendazole had
extended progression-free survival when compared with mice
treated with untargeted liposomes containing docetaxel alone
(p= 0.038), mebendazole alone (p= 0.007) or no active drug
(empty liposomes) (p= 0.0008), as well as with untreated mice
(p= 0.0007) (Fig. 6c). The median progression-free survival was
extended by 5 and 6.5 days compared with docetaxel and
mebendazole alone, respectively (Supplementary Table S5).
Furthermore, in a direct comparison of untargeted and Tf-
targeted liposomes entrapping both drugs, the delivery of the
loaded liposomes via transferrin further extended the duration of
progression-free survival in treated animals (p= 0.048).
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DISCUSSION
Drug repurposing may have a transformative impact on precision
medicine,21 fast-tracking novel treatment strategy using agents
that would otherwise not be implicated by conventional
approaches. Strategies for drug repurposing include a
chemogenomic library in phenotypic screen,22 in silico computa-
tional drug repositioning,23 pairwise combinatorial screen of
drugs against molecular targets of interest24 and novel in vivo
model systems such as zebraﬁsh.25 The use of cytotoxic
docetaxel chemotherapy is well established in metastatic
prostate cancer, but only results in a modest survival beneﬁt.
Cabazitaxel is approved by the FDA as a second-line chemother-
apy treatment; however, again the survival beneﬁt is only
moderate, leaving an unmet need for improved therapies.26 Our
drug-repurposing screen was designed to identify drugs that
could synergise with docetaxel and bring forward as clinical
candidate(s) as part of a combination therapeutics to treat
advanced prostate cancer. To date, none of the earlier efforts to
identify a synergiser for docetaxel in prostate cancer using a
candidate approach have been conﬁrmed in patients.27,28 We
hypothesised that a drug-repurposing screen using murine
prostate cancer cells harbouring genetic lesions implicated in
treatment resistance may identify authentic hits that would not
otherwise have been revealed using long-term cultured human
cancer cell lines. The genotypes driving carcinogenesis in CP2
and SP1 cells represent a signiﬁcant proportion (> 60%) of
invasive prostate cancer (Supplementary Fig. S1A).
The use of docetaxel in a screen was technically challenging as
it has a largely ‘all or nothing’ effect on cells, resulting in a steep
dose curve. It was difﬁcult to accurately achieve an EC30 for
docetaxel in the screen; we observed a lower-than-desired
percentage inhibition in the SP1 cells, likely the main reason for
fewer hits in these cells. Nonetheless, the screen revealed a
number of interesting drugs that could potentially work in
combination with docetaxel. The drug family that showed the
greatest synergy with docetaxel was the anthelmintic family.
Mebendazole has been studied in isolation in several cancer types
(adrenocortical carcinoma, melanoma, HNSCC and colon,29–32
including an ongoing Phase I study in paediatric brain tumours,
NCT02644291). As an anti-parasitic drug, the dosage of mebenda-
zole varies according to speciﬁc infections. Pinworms only require
a single treatment, while treatment for echinococcosis may
require a prolonged course. Side effects can include abdominal
pain and diarrhoea. In general, mebendazole is very well tolerated,
making it an excellent candidate for repurposing.33 Based on the
combination index analysis, mebendazole convincingly synergised
docetaxel-mediated growth inhibition in vitro, with greatest
synergism observed at low concentrations, suggesting an appeal-
ing therapeutic window. Our data were in keeping with previous
studies examining taxanes combined with vinca alkaloids (agents
that disrupt microtubule function by inhibiting depolymerisation),
which also demonstrated synergism at low doses, and additive or
antagonistic effects at higher doses.34,35 Mechanistically, com-
bined docetaxel and mebendazole reduced microtubule assembly
and drastically impaired microtubule dynamics, resulting in
aberrant cell division with frequent formation of multipolar
spindles, aneuploid daughter cells or arrest in prometaphase.
Mebendazole alone has a dramatic effect on microtubule
assembly, yet mitosis was largely unaffected (unlike docetaxel that
had the opposite effect). This perhaps suggests that supressing
microtubule assembly alone is not enough to perturb mitosis, and
that the synergy of the two drugs can have more impact on
mitosis due to reduced microtubule turnover. Docetaxel reduces
shrinkage of microtubules, and from the mitotic progression
experiments, it is clear that growing slower does not have large
effects on mitotic outcome, but being less able to shrink
microtubules produced a signiﬁcant problem for mitosis. Like
mebendazole, colchicine did not initiate aneuploidy in A549
cells36 but synergised with docetaxel, albeit less potently, high-
lighting the impact of dual-targeting microtubules. Importantly,
cells that are resistant to docetaxel were still susceptible to growth
inhibition by mebendazole. Our observations are in keeping with a
recent study on breast cancer cells, which demonstrated that
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Fig. 6 Tumour growth studies in a PC3M-Luc-G5 murine model.
a PC3M-Luc-G5 cells were subcutaneously injected into male
immunodeﬁcient BALB/c mice, and when tumours were palpable
and reached a diameter of 5mm, the animals were randomised to
receive intravenous administration of untargeted liposomes entrap-
ping docetaxel and mebendazole (DOC+MBZ), docetaxel only (DOC)
or mebendazole only (MBZ), along with control mice that were either
untreated or injected with empty liposomes. In addition, a group of
mice were injected with transferrin (Tf)-bearing liposomes entrapping
DOC+MBZ for a focused comparison with untargeted liposomes
entrapping DOC+MBZ. n= 10 (except for Tf DOC+MBZ, n= 8),
mean values ± SEM are shown. b Overall tumour (n= 10) response at
the end of treatment, classiﬁed in accordance with the Response
Evaluation Criteria in Solid Tumours (RECIST), where progressive
disease= increase in relative tumour volume higher than 1.2-fold,
stable disease= relative volume between 0.7 and 1.2 and partial
response=measurable tumour with a volume reduction of more than
30% (0–0.70). c Progression-free survival curves. The y axis gives the
proportion of tumours that are progressing over time. Progression-
free survival was deﬁned as < 20% increase in tumour volume from
day 1. n= 10 (except for Tf DOC+MBZ, n= 8), analysed by log-rank
(Mantel–Cox) test, *p < 0.05.
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docetaxel-resistant cells were more sensitive to treatment with
colchicine (and other colchicine-site-binding agents) than their
parental cells, while other microtubule-targeting agents binding at
other sites were less effective.37 Taken together, our data show
that the combination of docetaxel and mebendazole could be
used to treat prostate cancer and potentially combat the issue of
docetaxel resistance. Non-tumorigenic RWPE prostatic epithelial
cells were less responsive to docetaxel and/or mebendazole
treatment (Supplementary Table S3 and Supplementary Fig. S3B),
suggesting a potential favourable therapeutic window.
AR pathway-independent forms of CRPC are increasing in
incidence with the advent of potent AR-targeting therapies, such
as enzalutamide and abiraterone. Besides taxane chemotherapy,
radium-223 can be used to treat AR-independent CRPC, particu-
larly for patients with bone metastases.38,39 For in vivo synergism
studies, we used PC3M cells that represent an AR-independent
CRPC form. As a proof-of-concept study, we originally undertook
an experiment where CD-1 nude mice were injected with PC3M
cells in the anterior prostate and treated with docetaxel (given
intraperitoneally) and/or mebendazole (given orally). We found
that the mice treated with docetaxel had severe abdominal
distension, resulting in removal from the study before the end of
treatment.40 To counteract this docetaxel-associated toxicity,
liposomes were employed to deliver docetaxel and mebendazole
to the tumour. Using this approach, we observed enhanced in vivo
efﬁcacy with combined treatment. In addition, we found that the
efﬁcacy could be further improved by targeting the liposomes to
tumour cells using transferrin.41 Liposome-mediated drug delivery
avoided the docetaxel-associated toxicities that we previously
observed. Future clinical study does not necessarily involve
liposomes as both drugs are extensively used clinically, and the
relative dosing of the two agents can be tested easily. Importantly,
the abdominal distension that we observed in mice treated with
unencapsulated docetaxel is not often observed in the clinic.
Future clinical studies of combined docetaxel and mebendazole
treatment in prostate cancer patients will incorporate careful
scheduling to determine the optimal treatment scheme to
produce synergism and at the same time minimise systemic
toxicity. As the relative dose of docetaxel required will be low, it
may be that combined treatment may produce enhanced efﬁcacy
without increased toxicities. Finally, colchicine, commonly used for
gout, is not known to increase treatment toxicity of docetaxel.
Collectively, our repurposing screen using prostate cancer cells
derived from genetically engineered mouse models identiﬁed
mebendazole as a clinical candidate to be combined with
docetaxel for synergistic cancer cell killing.
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